Novel Role of PPAR-Gamma in GM-CSF Induced Anti-Tumor Immunity
CitationGoyal, Girija. 2015. Novel Role of PPAR-Gamma in GM-CSF Induced Anti-Tumor Immunity. Doctoral dissertation, Harvard University, Graduate School of Arts & Sciences.
AbstractGranulocyte macrophage colony stimulating factor (GM-CSF) mediates context dependent anti- or pro-inflammatory functions through cells of the myeloid lineage. GM-CSF signaling induces the expression of the transcription factor peroxisome proliferator-activated receptor gamma (PPAR-γ). We examined the role PPAR-γ in myeloid cells in the anti-tumor response to GVAX, a GM-CSF based cancer immunotherapy using the B16 model of murine melanoma.
We found that selective loss of PPAR-γ in the myeloid lineage using LysM-Cre reduces the efficacy of GVAX which could not be explained by known mechanisms. RNASeq of GVAX draining lymph node identified an increase in regulatory T-cells markers such as FoxP3 and coinhibitory receptors CTLA-4 and TIGIT in LysM-Cre; PPAR-γ fl mice (PPAR-γ KO). We confirmed by flow cytometry that Treg frequency was indeed increased in PPAR-γ KO lymph node with a strong reduction seen in the ratio of CD8 T-cells to regulatory T cell (CD8:Treg). Treg recruiting chemokines CCL17 and CCL22 were upregulated in the draining lymph node. Importantly, tumors in PPAR-γ KO mice had a reduced CD8:Treg ratio explaining the loss in GVAX efficacy.
Pharmacological activation or inactivation of PPAR-γ in GM-CSF treated human PBMC showed conservation of the role of PPAR-γ in regulating T-cell numbers in humans. PPAR-γ agonism in mice, using the FDA-approved small molecule ligand rosiglitazone (Rosi), improved CD8:Treg ratios in the vaccine draining lymph node and tumors. The gain-of-function data suggested the Rosi could be used as an adjunct to immunotherapy. All intratumoral Treg expressed high levels of CTLA-4 and TIGIT. Thus, we tested the impact of Rosi on the response to GVAX and anti-CTLA-4 combination therapy. We found that Rosi improved the tumor incidence and overall survival of tumor bearing mice treated with GVAX and anti-CTLA4.
Our data have identified a novel role of PPAR-γ in myeloid cells in regulating Treg numbers. This pathway is conserved in humans as seen in ex-vivo studies of PBMC. Further, we provide preclinical evidence that Rosi can be used to improve immunotherapeutic responses by increasing the ratio between intratumoral effector and regulatory cells.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:14226102
- FAS Theses and Dissertations